Postmarketing Surveillance Study of Anticholinergics - Prescribing Pattern and Therapeutic Long Term Value in Patients Suffering From Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD)

Boehringer Ingelheim

Status: Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Treatments: Drug: Atrovent®; Drug: Ventilat®

Study type: Observational

Funder types: Industry

Identifiers

NCT02238184

244.2499

Details and patient eligibility

About

To obtain further information on the prescribing pattern and therapeutic long term value in patients suffering from moderate or severs Chronic Obstructive Pulmonary Disease under conditions of daily practice

Enrollment: 105 patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients of both genders older than 40 years, who suffer from moderate or severe Chronic Obstructive Pulmonary Disease

• Only patients who showed following diagnosis parameters were to be considered for inclusion

  • FEV1 (Forced expiratory volume in 1 second) and FEV1/VC (vital capacity) <70%
  • Reversibility FEV1 <12% in the last 6 months
  • Smoker or Ex-smoker (>10 Pack years)
  • Asthma to be excluded

Exclusion criteria

• Contraindications listed in the Instructions for Use/Summary of Product Characteristics

Trial design

105 participants in 2 patient groups

Chronic Obstructive Pulmonary Disease

Description:

patients receiving Atrovent®

Treatment:

Drug: Atrovent®

Cronic Obstructive Pulmonary Disease

Description:

patients receiving Ventilat®

Treatment:

Drug: Ventilat®